Obstetric atypical hemolytic uremic syndrome: THE FIRST RUSSIAN EXPERIENCE OF DIAGNOSIS AND TREATMENT

Atypical hemolytic uremic syndrome (AHUs) in 12-31% of cases is associated with pregnancy or delivery, and may determine the prognosis of both mother and child. AIM: Analysis of clinical manifestations, features of course and outcomes of obstetric aHUS. PATIENTS AND METHODS: From 2012 to 2015 were observed 17 patients aged 19 to 38 years, in whom aHUS developed during pregnancy or directly after delivery. RESULTS: The development of aHUS was preceded by a mainly preeclampsia and/or HELLP syndrome and other pregnancy complications, diarrhea. All patients had complete symptom complex of thrombotic microangiopathy (TMA): sharp decrease of hemoglobin level (67,7 ± 15,9 g/l) with signs of microangiopathic hemolysis (increased LDH levels 2737,3 ± 3276,7 U/l, schistocytosis), thrombocytopenia (55,9±30.9 thousand in mcl.), acute kidney injury (hypercreatininemia 447.6 ±of 226.7 mg/DL, oliguria or anuria). Most patients (82%, 14 of 17) had first time mentioned arterial hypertension. In all patients the TMA was of a systemic nature: the signs of damage of liver, central nervous system, lungs had 73% of women (13 of 17), heart - 41% (7 of 17). In the analysis of flow aHUS depending on the stages of pregnancy at the time of the disease development clinical and laboratory parameters were more severe in women with manifestations of AHUs in the third trimester and after delivery. Treatment included plasma exchange and/or plasma infusions (14 of 17, 82%) with following Eculizumab treatment in 7 patients. Maternal mortality was 29%. CONCLUSION. Obstetric aHUS is characterized by the development of multiple organ failure in most patients. Development aHUS preceded by various complement-activating state. It seems that complications of pregnancy, not the pregnancy per se, are triggers of aHUS in women with a genetic predisposition to its development.

HELLP-синдром, thrombotic microangiopathy, atypical hemolytic uremic syndrome, pregnancy, preeclampsia, HELLP-syndrome

1. Fakhouri F1, Vercel C, Frémeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 2012 Dec;7(12):2100-2106

2. Machado S, Figueiredo N, Borges A et al. Acute kidney injury in pregnancy: a clinical challenge. J Nephrol 2012;25(01):19-30

3. Tsai HM. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfus Med Rev 2014; Oct;28(4):187-197

4. Fakhouri F, Fremeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura. Nat Clin Pract Nephrol 2007; 3: 679-687

5. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676-1687

6. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med2013 Sep;24(6):496-502.

7. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-867

8. Ganesan C, Maynard SE. Acute kidney injuryin pregnancy: the thrombotic microangiopathies. J Nephrol 2011;24(05)554-563

9. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin lApheresis 2001;16:202-209

10. Girardi G, Bulla R, Salmon JE, Tedesco F The complement system in the pathophysiology of pregnancy. Mol Immunol 2006;43:68-77

11. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859

12. Buurma A, Cohen D, Veraar K. Preeclamsia is characterized by placental complement dysregulation. Hypertension 2012;60(5):1332-1337

13. Rampressad R, Barton A, Sadovsky Y Nelson DM. The 5b-9 membrane attack complex of complement activation localizes to villous trophoblast injuri in vivo and modulates human trophoblast function in vitro. Placenta 2008;29(10):855-886

14. Lynch AM, Murphy JR, Byers T. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008;198(4):385-389

15. Dennya KJ, Coultharda LG, Finnellc RH. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol 2013;97:211-216

16. Hoffman MC, Rumer KK, Kramer A et al. Maternal and fetal alternative complement pathway activation in early severe preeclamsia. Am J Reproduct Immunol 2014;71:55-60

17. Girardi G, Yarilin D, Thurman JM et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Experiment Med 2006;203:2165-2175

18. Maynard SE, Min JY Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelian dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658

19. Eremina V, Jefferson A, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1139

20. Fang C, Richards A, Liszewski MK et al. Advances in understanding of pathogens is of aHUS and HELLP. Brit J Haematol 2008;143:336-348

21. Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009; 18(10):905-912

22. Hofer J, Rosales A, Fisher C, Giner T. Extra-renal manifestation of complement-mediates thrombotic microangiopathies. Pediatric Nephrology 2014; 2: doi:10.3389/fped.2014.00097

23. Лора Ш, Фремю-Бачи В. Атипичный гемолитико-уремический синдром. Нефрология 2012;16(2):16-48

24. Owens MY, Martin JN, Wallace K et al. Postpartum thrombotic microangiopathic syndrome. Transfusion Apheresis Sci 2013;48:51-57

25. Iannuzzi M, Siconolfi P, D'Angelillo A et al. A postpartum hemolytic uremic syndrome-like syndrome in a patient with preeclampsia: description of a clinical case. Transfus Apher Sci 2006;34:11-140

26. Obeidat B, MacDougall J, Harding K. Plasma exchange in a woman with thrombotic thrombocytopenic purpura or severe preeclampsia. Br J Obstet Gynecol 2002;109:961-962

27. Roberts G, Gordon MM, Porter D et al. Acute renal failure complicated HELLP syndrome, SLE and antiphospholipid syndrome: successful outcome using plasma exchange therapy. Lupus 2003;12:251-257

28. Козловская НЛ, Меркушева ЛИ, Кирсанова ТВ, Рунихина НК. Особенности течения и исхода атипичного гемолитико-уремического синдрома при беременности. Клин нефрол 2012; (3):44-49

29. Коротчаева ЮВ, Козловская НЛ, Бондаренко ТВ, Веселов ГА. Особенности течения и лечения «акушерского» гемолитико-уремического синдрома Нефрология 2015; 19 (2):76-81

30. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013; 34: 201-203

31. Mackaness DO, Craig A. Eculizumab in the Successful Treatment of Postpartum Hemolytic Uremic Syndrome - A Case Report. NKF 2014 Spring Clinical Meetings Abstracts. Am J Kidney Dis 2014; 63(5):75

32. Kourouklaris A, Ioannou K, Athanasiou L et al. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 2014; 8:307